Covered recipient · General Payments record
TIMOTHY CRAIG ROMANOSKI
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,852.33
- Reported across 117 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $405.83 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $197.41 | 6 |
| Acerta Pharma LLC | $48.25 | 2 |
| PFIZER INC. | $34.28 | 2 |
| Insmed, Inc. | $27.36 | 1 |
| Corcept Therapeutics | $21.11 | 1 |
| Amgen Inc. | $20.97 | 1 |
| Astellas Pharma US Inc | $19.41 | 1 |
| Mylan Specialty L.P. | $18.54 | 1 |
| DEXCOM, INC. | $18.50 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $20.97 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116066527 | CMS |
| Astellas Pharma US Inc | $19.41 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139293366 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.35 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105511425 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.90 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105471649 | CMS |
| Corcept Therapeutics | $21.11 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117752986 | CMS |
| Dexcom, Inc. | $18.50 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153341219 | CMS |
| Insmed, Inc. | $27.36 | 12/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089568629 | CMS |
| Mylan Specialty L.P. | $18.54 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147308480 | CMS |
| Novo Nordisk Inc | $17.65 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097677343 | CMS |
| Novo Nordisk Inc | $22.31 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096593322 | CMS |
| Novo Nordisk Inc | $92.46 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096665990 | CMS |
| Novo Nordisk Inc | $17.10 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097642738 | CMS |
| Novo Nordisk Inc | $23.51 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096750482 | CMS |
| Novo Nordisk Inc | $24.38 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097141345 | CMS |
| PFIZER INC. | $15.73 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131320163 | CMS |
| PFIZER INC. | $18.55 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131613702 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.